124 related articles for article (PubMed ID: 26021996)
1. Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens.
Harrington PR; Fleischer R; Connelly SM; Lewis LL; Murray J
Clin Infect Dis; 2015 Sep; 61(6):974-7. PubMed ID: 26021996
[TBL] [Abstract][Full Text] [Related]
2. Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin.
Merli M; Messina E; Salpietro S; Lazzarin A; Uberti-Foppa C; Hasson H
Clin Infect Dis; 2016 Feb; 62(4):527-8. PubMed ID: 26508514
[No Abstract] [Full Text] [Related]
3. Reply to Merli et al.
Harrington PR; Fleischer R; Connelly SM; Lewis LL; Murray J
Clin Infect Dis; 2016 Feb; 62(4):528-9. PubMed ID: 26508511
[No Abstract] [Full Text] [Related]
4. Combination treatment for hepatitis C can be hazardous in patients co-infected with HIV.
Schvarcz R; Moberg L; Sönnerborg A
Antivir Ther; 1998; 3(4):233-4. PubMed ID: 10682144
[No Abstract] [Full Text] [Related]
5. Adverse effects of peg-Interferon and Ribavirin combined antiviral treatment in a Romanian hepatitis C virus infected cohort.
Predescu O; Streba LA; Irimia E; Streba L; Mogoantă L
Rom J Morphol Embryol; 2012; 53(3):497-502. PubMed ID: 23010773
[TBL] [Abstract][Full Text] [Related]
6. [Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].
Zheng YH; He Y; Yang X; Gong GZ; Zhou HY; Zhang CY; Zhou W; Huang L; Ding PP; Li H
Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):741-4. PubMed ID: 16248945
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.
Hoofnagle JH; Ghany MG; Kleiner DE; Doo E; Heller T; Promrat K; Ong J; Khokhar F; Soza A; Herion D; Park Y; Everhart JE; Liang TJ
Hepatology; 2003 Jul; 38(1):66-74. PubMed ID: 12829988
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus: standard-of-care treatment.
Pawlotsky JM
Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
[TBL] [Abstract][Full Text] [Related]
9. Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection.
Neau-Cransac M; Foucher J; Ledinghen VD; Bernard PH; Legrand E; Lafon ME
Viral Immunol; 2005; 18(1):197-204. PubMed ID: 15802964
[TBL] [Abstract][Full Text] [Related]
10. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
[TBL] [Abstract][Full Text] [Related]
11. Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C.
Wirth S; Lang T; Gehring S; Gerner P
Hepatology; 2002 Nov; 36(5):1280-4. PubMed ID: 12395341
[TBL] [Abstract][Full Text] [Related]
12. Future perspectives: towards interferon-free regimens for HCV.
Gane E
Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
[TBL] [Abstract][Full Text] [Related]
13. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.
Rallón NI; Morello J; Labarga P; Benito JM; Rodríguez-Nóvoa S; Vispo E; Barreiro P; Castro MÁ; Aguirrebengoa K; Pineda JA; Miralles P; Tellez MJ; Portu J; Miralles C; Ocampo A; Soriano V;
Clin Infect Dis; 2011 Dec; 53(12):1291-5. PubMed ID: 22028438
[TBL] [Abstract][Full Text] [Related]
14. Interferon plus ribavirin: a cautionary note.
Macedo G; Ribeiro T
Am J Gastroenterol; 1999 Oct; 94(10):3087-8. PubMed ID: 10520894
[No Abstract] [Full Text] [Related]
15. Naïve CD4+ T Cell Lymphopenia and Apoptosis in Chronic Hepatitis C Virus Infection Is Driven by the CD31+ Subset and Is Partially Normalized in Direct-Acting Antiviral Treated Persons.
Auma AWN; Shive CL; Lange A; Damjanovska S; Kowal C; Zebrowski E; Pandiyan P; Wilson B; Kalayjian RC; Canaday DH; Anthony DD
Front Immunol; 2021; 12():641230. PubMed ID: 33912168
[TBL] [Abstract][Full Text] [Related]
16. [Peripheral facial paralysis during interferon treatment in hepatitis C: recovery without antiviral therapy withdrawal].
de Artaza T; Sánchez JJ; González C; Pérez-Grueso MJ; Repiso A; Gómez R; Potenciano JL
Gastroenterol Hepatol; 2004; 27(7):434-5. PubMed ID: 15461949
[No Abstract] [Full Text] [Related]
17. [Type 2 diabetes mellitus with histological finding of nonalcoholic steatohepatitis following combination therapy with interferon and ribavirin for chronic hepatitis C].
Yagi N; Uchikoga O; Nishumi T; Shibutani Y; Fukunaga K; Yagi N; Morita M; Tani S; Murao S
Nihon Shokakibyo Gakkai Zasshi; 2005 Aug; 102(8):1045-50. PubMed ID: 16124712
[No Abstract] [Full Text] [Related]
18. Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C.
Guyader D; Poinsignon Y; Cano Y; Saout L
J Hepatol; 2002 Aug; 37(2):289-91. PubMed ID: 12127440
[No Abstract] [Full Text] [Related]
19. Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy.
Ravens S; Hengst J; Schlapphoff V; Deterding K; Dhingra A; Schultze-Florey C; Koenecke C; Cornberg M; Wedemeyer H; Prinz I
Front Immunol; 2018; 9():510. PubMed ID: 29616028
[TBL] [Abstract][Full Text] [Related]
20. You're not the one: treating subjects co-infected with hepatitis C genotypes 2 and 3 and human immunodeficiency virus.
Pearlman BL; Lim TH
Dig Dis Sci; 2014 Aug; 59(8):1681-3. PubMed ID: 25002310
[No Abstract] [Full Text] [Related]
[Next] [New Search]
